Journal of International Oncology ›› 2022, Vol. 49 ›› Issue (12): 705-710.doi: 10.3760/cma.j.cn371439-20220725-00139
Received:
2022-07-25
Revised:
2022-09-22
Online:
2022-12-08
Published:
2023-01-05
[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
doi: 10.3322/caac.21660 |
[2] |
Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054): 1883-1892. DOI: 10.1016/S0140-6736(16)31388-5.
doi: S0140-6736(16)31388-5 pmid: 27567279 |
[3] |
Lang J, Hu C, Lu T, et al. Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives[J]. Cancer Manag Res, 2019, 11: 6365-6376. DOI: 10.2147/CMAR.S197544.
doi: 10.2147/CMAR.S197544 pmid: 31372041 |
[4] |
Lee AW, Ng WT, Pan JJ, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma[J]. Radiother Oncol, 2018, 126(1): 25-36. DOI: 10.1016/j.radonc.2017.10.032.
doi: S0167-8140(17)32686-5 pmid: 29153464 |
[5] | 罗京伟, 徐国镇, 高黎. 头颈部肿瘤放射治疗图谱[M]. 3版. 北京: 人民卫生出版社, 2020. |
[6] |
中国鼻咽癌临床分期工作委员会. 2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J]. 中华放射肿瘤学杂志, 2011, 20(4): 267-269. DOI: 10.3760/cma.j.issn.1004-4221.2011.04.001.
doi: 10.3760/cma.j.issn.1004-4221.2011.04.001 |
[7] |
中国医师协会放射肿瘤治疗医师分会; 中华医学会放射肿瘤治疗学分会. 中国鼻咽癌放射治疗指南(2020版)[J]. 中华肿瘤防治杂志, 2021, 28(3): 167-177. DOI: 10.16073/j.cnki.cjcpt.2021.03.01.
doi: 10.16073/j.cnki.cjcpt.2021.03.01 |
[8] |
Xue F, Hu C, He X. Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3-4 nasopharyngeal carcinoma[J]. Onco Targets Ther, 2017, 10: 3329-3336. DOI: 10.2147/OTT.S140420.
doi: 10.2147/OTT.S140420 |
[9] |
Yang H, Chen X, Lin S, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a prospective, multi-center, randomized clinical trial[J]. Radiother Oncol, 2018, 126(1): 37-42. DOI: 10.1016/j.radonc.2017.07.020.
doi: S0167-8140(17)32479-9 pmid: 28864073 |
[10] |
Zhao C, Miao JJ, Hua YJ, et al. Locoregional control and mild late toxicity after reducing target volumes and radiation doses in patients with locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy (IC) followed by concurrent chemoradiotherapy: 10-year results of a phase 2 study[J]. Int J Radiat Oncol Biol Phys, 2019, 104(4): 836-844. DOI: 10.1016/j.ijrobp.2019.03.043.
doi: 10.1016/j.ijrobp.2019.03.043 |
[11] |
Hiyama T, Kuno H, Sekiya K, et al. Bone subtraction iodine imaging using area detector CT for evaluation of skull base invasion by nasopharyngeal carcinoma[J]. AJNR Am J Neuroradiol, 2019, 40(1): 135-141. DOI: 10.3174/ajnr.A5906.
doi: 10.3174/ajnr.A5906 |
[12] |
Becker M, Zbären P, Delavelle J, et al. Neoplastic invasion of the laryngeal cartilage: reassessment of criteria for diagnosis at CT[J]. Radiology, 1997, 203(2): 521-532. DOI: 10.1148/radiology.203.2.9114116.
doi: 10.1148/radiology.203.2.9114116 pmid: 9114116 |
[13] |
Shatzkes DR, Meltzer DE, Lee JA, et al. Sclerosis of the pterygoid process in untreated patients with nasopharyngeal carcinoma[J]. Radiology, 2006, 239(1): 181-186. DOI: 10.1148/radiol.2391042176.
doi: 10.1148/radiol.2391042176 pmid: 16507751 |
[14] |
Boonrod A, Phuttharak W, Ounjaroen N. Prevalence of sclerotic pterygoid plate in pretreatment nasopharyngeal carcinoma[J]. Asian Pac J Cancer Prev, 2022, 23(4): 1193-1197. DOI: 10.31557/APJCP.2022.23.4.1193.
doi: 10.31557/APJCP.2022.23.4.1193 |
[15] |
Niu X, Chang X, Gao Y, et al. Using neoadjuvant chemotherapy and replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma with intracranial invasion to protect critical normal tissue[J]. Radiat Oncol, 2013, 8: 226. DOI: 10.1186/1748-717X-8-226.
doi: 10.1186/1748-717X-8-226 pmid: 24083351 |
[16] |
Wang RH, Zhang SX, Zhou LH, et al. Volume and dosimetric va-riations during two-phase adaptive intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma[J]. Biomed Mater Eng, 2014, 24(1): 1217-1225. DOI: 10.3233/BME-130923.
doi: 10.3233/BME-130923 |
[17] |
Chitapanarux I, Chomprasert K, Nobnaop W, et al. A dosimetric comparison of two-phase adaptive intensity-modulated radiotherapy for locally advanced nasopharyngeal cancer[J]. J Radiat Res, 2015, 56(3): 529-538. DOI: 10.1093/jrr/rru119.
doi: 10.1093/jrr/rru119 pmid: 25666189 |
[18] |
Hu YC, Tsai KW, Lee CC, et al. Which nasopharyngeal cancer patients need adaptive radiotherapy?[J]. BMC Cancer, 2018, 18(1): 1234. DOI: 10.1186/s12885-018-5159-y.
doi: 10.1186/s12885-018-5159-y |
[19] |
Jin X, Han C, Zhou Y, et al. A modified VMAT adaptive radio-therapy for nasopharyngeal cancer patients based on CT-CT image fusion[J]. Radiat Oncol, 2013, 8: 277. DOI: 10.1186/1748-717X-8-277.
doi: 10.1186/1748-717X-8-277 |
[20] |
King AD, Vlantis AC, Bhatia KS, et al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy[J]. Radiology, 2011, 258(2): 531-537. DOI: 0.1148/radiol.10101241.
doi: 10.1148/radiol.10101241 pmid: 21131580 |
[21] | 王孝深. 鼻咽癌精确放疗的靶区勾画:依据、原则与细节[M]. 北京: 中国科学技术出版社, 2021. |
[22] |
Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4): 1071-1078. DOI: 10.1016/j.ijrobp.2008.12.015.
doi: 10.1016/j.ijrobp.2008.12.015 |
[23] |
Zhang S, Yang S, Xu P, et al. Variations of clinical target volume delineation for primary site of nasopharyngeal cancer among five centers in China[J]. Front Oncol, 2020, 10: 1572. DOI: 10.3389/fonc.2020.01572.
doi: 10.3389/fonc.2020.01572 pmid: 32974193 |
[24] | McHanwell S. Pharynx[M]// StandringS, GleesonM. Gray's anatomy. Amsterdam: Elsevier, 2016: 572-575. |
[25] |
Schmidt-Ullrich RK, Buck D, Dogan N, et al. IMRT for carcinomas of the oropharynx and oral cavity[M]// BortfeldT, Schmidt-UllrichR, De NeveW, et al. Image-guided IMRT. Berlin, Heidelberg: Springer, 2006: 301-317. DOI: 10.1007/3-540-30356-1_24.
doi: 10.1007/3-540-30356-1_24 |
[26] |
Lauve A, Morris M, Schmidt-Ullrich R, et al. Simultaneous inte-grated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: Ⅱ—clinical results[J]. Int J Radiat Oncol Biol Phys, 2004, 60(2): 374-387. DOI: 10.1016/j.ijrobp.2004.03.010.
doi: 10.1016/j.ijrobp.2004.03.010 |
[27] |
Paganetti H, Parodi K, Jiang H, et al. Comparison of pencil-beam and Monte Carlo calculated dose distributions for proton therapy of skull-base and para-spinal tumors[C]// World Congress on Medical Physics and Biomedical Engineering 2006, Berlin, Heidelberg: Springer, 2007: 2219-2222. DOI: 10.1007/978-3-540-36841-0_560.
doi: 10.1007/978-3-540-36841-0_560 |
[28] |
Asher D, Amestoy W, Studenski MT, et al. Dosimetric comparison of intensity-modulated radiation therapy for early-stage glottic cancers with and without the air cavity in the planning target volume[J]. Med Dosim, 2019, 44(4): 405-408. DOI: 10.1016/j.meddos.2019.02.007.
doi: S0958-3947(19)30033-0 pmid: 30928177 |
[29] |
Wadi-Ramahi SJ, Bernard D, Chu JC. Effect of ethmoid sinus cavity on dose distribution at interface and how to correct for it: magnetic field with photon beams[J]. Med Phys, 2003, 30(7): 1556-1565. DOI: 10.1118/1.1578484.
doi: 10.1118/1.1578484 pmid: 12906173 |
[30] |
Behrens CF. Dose build-up behind air cavities for Co-60, 4, 6 and 8 MV. Measurements and Monte Carlo simulations[J]. Phys Med Biol, 2006, 51(22): 5937-5950. DOI: 10.1088/0031-9155/51/22/015.
doi: 10.1088/0031-9155/51/22/015 pmid: 17068375 |
[31] | 柏树令. 系统解剖学[M]. 6版. 北京: 人民卫生出版社, 2004. |
No related articles found! |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||